Literature DB >> 24834280

The effect of an aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease.

Manochehr Khaoshbaten1, Nasrin Gholami1, Saied Sokhtehzari2, Amir Hossein Monazami3, Mazhar Rostami Nejad4.   

Abstract

AIM: The aim of this study was to evaluate the effect of an aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease.
BACKGROUND: Non alcoholic fatty liver disease (NAFLD) has different prevalence in various parts of the world. Obesity and low physical activity are main risk factors for the development of NAFLD. PATIENTS AND METHODS: Ninety patients diagnosed by ultrasound as NAFLD was evaluated in a clinical trial as case (A) and control groups (B). The effect of aerobic exercise on changing in liver enzymes and liver echogenicity was assessed in cases compared with control group which were only on medical therapy.
RESULTS: The mean age in the sample group was 37.6±8.3 in the 17-56 yrs age range. In group A, fatty liver was in stage I in 26 (57.8%) cases, stage II in 17 (37.8%), and stage III in 2 (4.4%). In group B, fatty liver was in stage I in 30 (66.7%) patients, in stage II in 14 (31.1%) and stage III in 1 (2.2%). After an aerobic exercise, serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease was significant improved in case group (ALT (P= 0.0001), AST (P = 0.01).
CONCLUSION: Considering the present study, we can suggest that a controlled aerobic exercise schedule can be helpful in the association of medical therapy in the treatment of NAFLD.

Entities:  

Keywords:  Aerobic exercise; Liver enzyme; NAFLD

Year:  2013        PMID: 24834280      PMCID: PMC4017540     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol Bed Bench        ISSN: 2008-2258


Introduction

Non alcoholic fatty liver disease (NAFLD) is a liver disorder that is accompanied with accumulation of triglisiride in hepatocyte. Pathologic changes in non alcoholic fatty liver disease are similar to alcoholic fatty liver disease but there is not any alcohol consumption or less than limit that can be damage to hepatocyte. These changes are in a spectrum from simple steatosis to steato hepataitis and finally fibrosis and then scirrhosis (1–5). NAFLD has different prevalence in various parts of the world, though 20-30% prevalence has been reported in epidemiologic studies in western countries (2, 6–8). This disease can be seen in all ages but often middle aged people are affected (8). Now there are multiple methods for the diagnosis of NAFLD in the world. Sonography is one of these methods that are applied to the diagnosis of this disease with ruling out of other probable disease (9). NAFLD is related to metabolic syndrome such as obesity, diabetes mellitus and hyperlipidemia. Since obesity and low physical activity are main risk factors for the development of NAFLD, life style modification considering weight loss and physical activity is thought to be as important alternative for treatment of this disease (10). A few studies performed regarding the quantity of the physical activity in NAFLD. But the advantages of physical activity has been shown very clearly (11). With considering of this reality surveying on specific affects of physical activity on non alcoholic fatty liver disease in the site of research is necessary. Therefore, the aim of present study was to evaluate the effect of an aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease.

Patients and Methods

In this non randomized clinical trial including 90 patients with established NAFLD divided equally in to case and control groups. The duration of this study was 12 months from December 2011 and December 2012. For the diagnosis of this disease, sonography with acceptable sensitivity and specificity was applied. Before the entering a patient to the study the height and weight of patient with minimal cloths was measured in both groups. For the measuring of height and weight SECA balance device has been used with the accuracy of 0.5 cm and 0.1 kg. Body Mass Index (BMI) was calculated with the using of weight/height2 in the start of the study in both groups. Also body composition of any patient in each group was determined in the start and the end of the study with the device of ZEUS9 bioelectrical impedance analysis. At the beginning of the study the measuring of liver enzymes (AST, ALT, ALP) and FBS and lipid profile (TG, Total cholesterol, HDL cholesterol) with enzymatic methods was measured. The level of LDL cholesterol was calculated with the formula of Fredwald, but if the level of TG was upper than 400 mg/dl, enzymatic methods was applied for the measuring of LDL cholesterol. On the other hands in control group medical therapy with 1000 mg vitamin C and 400 units vitamin E was prescribed. In case group in addition to the medical therapy similar to control group, thirty minutes aerobic exercise with maximal heart rate three times a week with the duration of three months was performed. At the end of the study, variation of the variables (mentioned above) in cases was compared with control group. Patients with alcohol consumption more than 20cc per day, drug usage, viral hepatotropic positive or Wilson's disease, autoimmune disease, cholestatic disorders, renal, cardiovascular or thyroid disease, and patents with history of gastric bypass surgery, paraentral nutrition or cachexicia were excluded from this study.

Statistical analysis

The results of the study represented as mean ± standard deviation (SD), percentage and abundance using SPSS software version 16. For the comparison of quantitative variables Student T test and for the comparison of qualitative variables Chi Square has been applied and in the cases in which predictive value was less than 0.05, this result recognized significant.

Results

Totally 57 subjects (63/3%) were male and 33 subjects (36.7%) were female. In group A (case group) 29 (64/4%) were male and 16 (35/6%) were female and in group B (control group) 28 individuals (62/2%) and 17 persons (37/8%) were male and female respectively. The mean age of whole patients was 37.6±8.3 ranged between 17-56 years old. The mean age in cases and control was 35.6±9.2 (17-54) and 39.5±6.9 (26-56) years old respectively. The statistical analysis showed a significant difference regarding mean age in two groups (P = 0.02). Basic data in studied groups are presented in Table 1. Table 1 showed no statistically difference in cases compare to controls. Also Table 2 showed that the mean of biochemical test in cases before and after an aerobic exercise only for ALT and AST was significant.
Table 1

Basic data in case and control groups

Case (n = 45)Control (n = 45)P-value
Height169.7±11.8* (120–188)168.3±9.9(147–189)0.56
Weight84.2±1.3(50–115)83.9±1.3(59–120)0.91
BMI 28.9±3.2(22.4–36.8)29.5±4.1(23–46.6)0.47
DBP 72.8±8.1(60–90)76.2±9.8(60–100)0.08

Mean± standard deviation (range)

Body mass index

Diastolic blood pressure

Table 2

The result of biochemical test in cases before and after an aerobic exercise

Variables* BeforeAfterP Value
FBS95.2±19.6(62–193)95.2±16(66–160)P = 0.98
TG218.2±12(82–687)188.6±8.6(36–398)P = 0.18
Total Chol190.6±35.5(124–294)194.9±38.8(90–284)P = 0.58
LDL108.1±31.3(49–184)112.2±36.1(38–197)P = 0.57
HDL42.4±9.7(27–71)45.3±8.8(29–71)P = 0.14
AST41.5±2.7(13–137)29±9.5(15–53)P = 0.006
ALT61.1±3.6(14–185)44.9±2.4(13–119)P = 0.01
Alk.P165.9±61.4(29–338)185±56.2(45–400)P = 0.12

Mean±SD; FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase

Basic data in case and control groups Mean± standard deviation (range) Body mass index Diastolic blood pressure The result of biochemical test in cases before and after an aerobic exercise Mean±SD; FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase After the completion of aerobic exercise duration in both groups, serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease was decrease. The degree of fatty liver in group A showed fatty stage 1 in 35 patients (77.8%), stage 2 in 4 patients(8.9%) and 6 patients(13.3%) without sonographic fatty liver. In group B fatty liver degree of 33 patients (73.3%) was in stage 1, 9 patients (20%) in stage 2 and fatty liver of 3 patients (6.7%) had been resolved by sonography. The difference in both groups was not statistically significant (P = 0.23). Weight, BMI FBS, TG, HDL, AST, ALT and VFM, kg was statistically significant by comparison of basic information description before and after trial in group A (P < 0.05) (Table 3). This result was statistically significant in control group for weight, BMI, SBP, DBP, TG and LBM (P < 0.05) (Table 4).
Table 3

The comparison of basic information description before and after trial in group A

Variable* Pre TrialPost TrialP Value
Weight84.2±1.382.1±11.90.0001
BMI28.9±3.228±2.80.0001
SBP112.7±14.9110.2±11.70.06
DBP72.8±8.171.9±14.40.35
FBS95.2±19.690.6±14.40.01
TG218.2±12176±5.20.002
Total Chol190.6±35.5183.2±25.60.09
LDL108.1±31.3100±26.20.06
HDL42.4±9.746.5±8.10.0001
AST41.5±2.734.3±15.10.01
ALT61.1±3.643.5±2.40.0001
Alk.P165.9±61.4157.9±54.20.12
VFM, kg3.8±13.7±1.10.0001

Mean± standard deviation FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase

Table 4

The comparison of basic information description before and after trial in group B

Variable* Pre TrialPost TrialP Value
Weight83.9±1.383.3±12.90.02
BMI29.5±4.129.4±4.10.04
SBP127.2±18.3123.4±17.70.0001
DBP76.2±9.872.8±10.80.006
FBS95.2±1694.3±13.40.2
TG188.6±8.6172.4±7.60.04
Total Chol194.9±38.8193.8±34.30.6
LDL112.2±36.1115.8±26.90.6
HDL45.3±8.846±8.40.5
AST29±9.528±9.90.2
ALT44.9±2.439.9±2.20.07
Alk.P185±56.2193.2±46.80.2
VFM, kg3.5±1.53.3±1.50.7
WHR0.9±0.10.9±0.070.2
Body Fat, kg23.2±6.122.9±6.80.6
LBM55±9.954.9±8.90.005

Mean±SD; FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase

The comparison of basic information description before and after trial in group A Mean± standard deviation FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase The comparison of basic information description before and after trial in group B Mean±SD; FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase

Discussion

As our results showed that NAFLD's pathologic changes are similar to pathologic changes that are seen in alcoholic fatty liver disease but there is not alcohol usage in NAFLD (1). NAFLD's prevalence is different in the worldwide, though 20-30% prevalence has been reported in epidemiologic studies in western countries (2). This disease can be seen in all ages but often middle aged people are more affected (8). Sotodeh et al. in 2006 studied the effect of aerobic exercise in patients with non alcoholic fatty liver disease. The finding of this study followed this kind of exercise and showed the decrease of liver enzymes level (12). In this study we showed the statistical significant decrease of AST, ALT and ALP level in NAFLD patients after an aerobic exercise. In addition to liver enzymes decrease in our study, the decrease of lipid profile in cases was statistically significant. In another study by Chen et al. in 2008, 23 patients with established NAFLD did intense cycling in duration of 2 hours a week for 10 weeks and they show that in the end of study the significant decrease in topography index, insulin resistance and sonographic finding (13). Also in our study body composition components such as body fat mass, visceral fat mass and body mass index and waist to hip ratio had statistical meaningful decrease but we couldn't show the statistically significant decrease in sonographically fat component in our patients. In a cross sectional study by Perseghin et al., the relation between physical activity and the component of liver's fat was reverse (14). In a meta-analytic survey in 2008, physical activity (aerobic or inaerobic) in 375 patients with NAFLD had protective effect such as decrease in lipid profile and body composition (15). In conclusion with respect of result of this study and comparison with the studies which is mentioned above we could conclude that in addition to medical therapy, controlled exercise trial can be helpful in the cure of non alcoholic fatty liver disease.
  12 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

Review 2.  Nonalcoholic steatohepatitis: what we know in the new millennium.

Authors:  Stephen A Harrison; Shailesh Kadakia; Kevin A Lang; Steven Schenker
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

Review 3.  Epidemiology of nonalcoholic fatty liver.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Clin Liver Dis       Date:  2004-08       Impact factor: 6.126

4.  Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Luciano Zenari; Giacomo Zoppini; Giancarlo Falezza
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

5.  Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease.

Authors:  Shi-Ming Chen; Chieh-Yu Liu; Shian-Rei Li; Hui-Ting Huang; Ching-Yen Tsai; Hei-Jen Jou
Journal:  J Chin Med Assoc       Date:  2008-11       Impact factor: 2.743

Review 6.  Nonalcoholic steatohepatitis: definition and pathology.

Authors:  E M Brunt
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

7.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

8.  Habitual physical activity is associated with intrahepatic fat content in humans.

Authors:  Gianluca Perseghin; Guido Lattuada; Francesco De Cobelli; Francesca Ragogna; Georgia Ntali; Antonio Esposito; Elena Belloni; Tamara Canu; Ileana Terruzzi; Paola Scifo; Alessandro Del Maschio; Livio Luzi
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

Review 9.  Advances in the understanding and treatment of nonalcoholic fatty liver disease.

Authors:  Stephen A Harrison; Adrian M Di Bisceglie
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

Authors:  Shira Zelber-Sagi; Dorit Nitzan-Kaluski; Rebecca Goldsmith; Muriel Webb; Izabel Zvibel; Ilana Goldiner; Laurie Blendis; Zamir Halpern; Ran Oren
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

View more
  7 in total

Review 1.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

Review 2.  Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury.

Authors:  Hans-Theo Schon; Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-08-30       Impact factor: 5.810

Review 3.  Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms.

Authors:  Hirokazu Takahashi; Kazuhiko Kotani; Kenichi Tanaka; Yuichiro Egucih; Keizo Anzai
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-15       Impact factor: 5.555

4.  Investigating the impact of eight weeks of aerobic and resistance training on blood lipid profile in elderly with non-alcoholic fatty liver disease: a randomized clinical trial.

Authors:  Mohammad Ebrahim Ghamarchehreh; Alireza Shamsoddini; Seyed Moayed Alavian
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

5.  Upper Normal Limit of Serum Alanine Aminotransferase and Its Association with Metabolic Risk Factors in Pars Cohort Study.

Authors:  Faeze Sehatpour; Alireza Salehi; Hossein Molavi Vardanjani; Hossein Poustchi; Abdullah Gandomkar; Reza Malekzadeh
Journal:  Middle East J Dig Dis       Date:  2020-01

Review 6.  The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease.

Authors:  Christian von Loeffelholz; Johannes Roth; Sina M Coldewey; Andreas L Birkenfeld
Journal:  Biomedicines       Date:  2021-12-07

7.  Effect of moderate exercises and curcumin on hepatic transcriptional factors associated with lipid metabolism and steatosis in elderly male rat.

Authors:  Minoo Shirpoor; Asghar Tofighi; Alireza Shirpoor; Masoumeh Pourjabali; Leila Chodari
Journal:  Res Pharm Sci       Date:  2021-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.